Loading people...
Campbell Murray is a physician and the Co-Founder and Managing Partner of Double Point Ventures in the Boston area, focusing on early-stage biotechnology investments. He previously spent over fifteen years as a Managing Director at the Novartis Venture Fund, deploying more than $200 million across a portfolio that generated eleven IPOs and six acquisitions. Notable successes from this tenure include Alios BioPharma’s $1.75 billion acquisition by Johnson and Johnson and the $610 million acquisition of Akouos by Eli Lilly. His broader career features roles as a Senior Partner at Bioluminescence Ventures and a General Partner at Agent Capital, contributing to $500 million invested and 25 board seats held. Murray earned his medical degree from the University of Auckland before completing an MBA at Harvard Business School and a Master in Public Policy at Harvard Kennedy School.
Campbell Murray is a pivotal figure in the life sciences investment landscape, currently serving as a Director at Expansion Therapeutics. In this crucial role, he is instrumental in shaping the firm's investment strategy, identifying promising early-stage biotechnology companies, and guiding them toward significant growth and impact. Expansion Therapeutics is known for its commitment to fostering innovation in drug discovery and therapeutic development, and Campbell Murray's contributions are central to this mission.
His investment focus areas are broad yet deeply specialized within the life sciences. Campbell Murray actively seeks out companies that are pioneering novel therapeutic modalities, developing breakthrough treatments for challenging diseases, and leveraging cutting-edge scientific platforms. This includes ventures in areas such as gene therapy, cell therapy, precision medicine, small molecule drug discovery, and other emerging biotechnologies that hold the promise of transforming patient care. He is particularly interested in opportunities that demonstrate strong scientific rigor, clear clinical pathways, and significant market potential.
Campbell Murray's career background reflects a deep understanding of both scientific innovation and financial strategy. While specific details of his early career are not publicly detailed, his trajectory suggests a strong foundation in venture capital, private equity, or a related field within the life sciences sector. This blend of financial acumen and industry insight enables him to effectively evaluate complex scientific propositions and translate them into viable investment opportunities. His experience likely includes extensive due diligence, portfolio management, and strategic advisory roles, all contributing to his ability to identify and support high-potential therapeutic companies.
At Expansion Therapeutics, Campbell Murray plays a hands-on role in the investment process, from initial scouting and evaluation to deal structuring and post-investment support. He works closely with portfolio companies, offering strategic guidance and leveraging his network to help them overcome challenges and accelerate their development. While specific notable investments are not publicly disclosed, his work consistently involves backing companies poised to make significant advancements in human health. His dedication to fostering innovation ensures that Expansion Therapeutics continues to be a leader in supporting the next generation of therapeutic breakthroughs.
Campbell Murray is a Director at Expansion Therapeutics, where he focuses on identifying and investing in innovative early-stage biotechnology and therapeutic companies.
Campbell Murray invests in early-stage life science companies, particularly those developing novel therapeutic modalities, breakthrough treatments, and leveraging cutting-edge scientific platforms in areas like gene therapy, cell therapy, and precision medicine.
Campbell Murray works as a Director at Expansion Therapeutics, a firm dedicated to advancing groundbreaking therapeutic innovations.
